T Cell Lymphoma clinical trials

Explore recruiting t cell lymphoma clinical trials.

Recruiting t cell lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

T Cell Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with advanced T-cell lymphoma.

France, Belgium, Spain, Poland, Italy, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA

Belgium, Spain, Germany, France

Therapeutic exploratory (Phase II) EU CTIS Study details

ROMIDEPSIN IN COMBINATION WITH CHOEP AS FIRST LINE TREATMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN YOUNG PATIENTS WITH NODAL PERIPHERAL T-CELL LYMPHOMAS: A PHASE I-II STUDY

Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

An Open-Label, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PTX-100 Monotherapy in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma.

Italy, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2/3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T- Cell Lymphoma

Poland, Germany, Italy, Spain, Hungary

Phase II and Phase III (Integrated) EU CTIS Study details

T Cell Lymphoma trials by city

T Cell Lymphoma in Toronto T Cell Lymphoma in Vancouver T Cell Lymphoma in Montreal T Cell Lymphoma in Calgary T Cell Lymphoma in Edmonton T Cell Lymphoma in Ottawa T Cell Lymphoma in Winnipeg T Cell Lymphoma in Quebec City T Cell Lymphoma in Hamilton T Cell Lymphoma in Kitchener T Cell Lymphoma in London T Cell Lymphoma in Halifax T Cell Lymphoma in New York T Cell Lymphoma in Los Angeles T Cell Lymphoma in Chicago T Cell Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease